Use this area to offer a short teaser of your email's content. Text here will show in the preview area of some email clients.


Viewpoint

By Dr Florent Mbo Kuikumbi,
Provincial coordinating physician of North Bandundu for the National Human African Trypanosomiasis Control Programme (DRC) Medical Director


Sleeping sickness has several facets. We have to cover all of the endemic areas with surveillance efforts, otherwise there will always be pockets than can later lead to epidemics. Today, for example, in Bandundu Province in the DRC, we can only say we are controlling the disease, not eliminating it. We have to be able to cover all of the disease pockets and follow them for some time. We can treat the patients at the level of the community, but the vector – the tse tse fly – that transmits the parasites from an infected person to a healthy one is still out there and will continue to transmit the disease as long as people are carrying the parasite.
More and Also access MSF's and FIND's Press Releases on this topic


Upcoming events

13-14 December 2012
Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations

This DNDi-MSF event aims to bring together key actors in global public health to reflect on progress and shortcomings on R&D for NTDs, consider the evidence and report on analyses of recent data, and chart out ways to effectively tackle current challenges by drawing on lessons from the past decade.
More
Register for the live webcast

Inclusion of first patients in Phase II/III study on fexinidazole for HAT

DNDi has commenced a Phase II/III clinical trial for fexinidazole to treat human African trypanosomiasis (or sleeping sickness) for stage 2 of the disease.  The trial is conducted in six sites in Democratic Republic of Congo and Central African Republic. Dr Antoine Tarral, Head of HAT Clinical Program explains how the best science and technology was brought into remote areas to launch this high quality standard clinical trial.
More
Listen to Dr. Antoine Tarral's Podcast

Voices for Neglected Diseases

Angèle, a subsistance farmer in Musenge village, Masimanimba, Democratic Republic of the Congo tells about her experience as a HAT patient: how she was diagnosed by a mobile team, how she arrived at the hospital, and how she was treated with NECT.
Read Angèle's story

Funding: Wellcome Trust granted USD 3 million to DNDi for Chagas

The grant will fund a three-year study involving for the first time non-human primates (macaques) naturally infected in their outdoor living environment with the parasite that causes Chagas disease, in Texas, to look for new biological markers measuring treatment efficacy for the leading parasitic killer of the Americas.
More

Publications on HAT in PLoS NTDs

A group of articles is covering different aspects of HAT, two of which DNDi authors, are published in PLoS NTDs and give an overview of current treatments, discovery, diagnostics and more.
More

G-Finder report 2012

The 2012 edtion of the G-Finder that reports on global investment in R&D of new products for neglected diseases was released on 3 December 2012. Bernard Pécoul, DNDi Executive Director, comments the findings and recommendations of the report.
More